Open Targets Platform: supporting systematic drug–target identification and prioritisation
By D. Ochoa, Andrew Hercules, M. Carmona, D. Suveges, Asier Gonzalez-Uriarte, Cinzia Malangone, Alfredo Miranda, Luca Fumis, D. Carvalho-Silva, M. Spitzer and 22 more. Nucleic Acids Res., 2020
400 citations recorded by the source corpus.
Abstract The Open Targets Platform (https://www.targetvalidation.org/) provides users with a queryable knowledgebase and user interface to aid systematic target identification and prioritisation for drug discovery based upon underlying evidence. It is publicly available and the underlying code is open source. Since our last update two years ago, we have had 10 releases to maintain and continuously improve evidence for target–disease relationships from 20 different data sources. In addition, we have integrated new evidence from key datasets, including prioritised targets identified from genome-wide CRISPR knockout screens in 300 cancer models (Project Score), and GWAS/UK BioBank statistical genetic analysis evidence from the Open Targets Genetics Portal. We have evolved our evidence scoring framework to improve target identification. To aid the prioritisation of targets and inform on the potential impact of modulating a given target, we have added evaluation of post-marketing adverse drug reactions and new curated information on target tractability and safety. We have also developed the user interface and backend technologies to improve performance and usability. In this article, we describe the latest enhancements to the Platform, to address the fundamental challenge that developing effective and safe drugs is difficult and expensive.
Subfields: Computational Theory and Mathematics, Immunology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/38cf8d61e98d6263cf05a78a0f0712f56c802c46
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Computational Theory and Mathematics
In Molecular Biology
- Oskar Hansson
- Chanjin Jung
- Jingyu Lee
- Bilal Shaker
- Dokyun Na
- Konstantinos D. Tsirigos
- Urmo Võsa
- Sajjad Ahmad
Citations in the corpus
- Search and sequence analysis tools services from EMBL-EBI in 2022 (2022, neutral): “Since the last update, Open Targets (15), VarSite (16), PDBe-KB (17), GWAS Catalog (18), EMPIAR (19), European Variation Archive Studies (20) and Cellosaurus (21) have been added as new resources.”
- In silico methods and tools for drug discovery (2021, background): “Several web servers such as Harmonizome [40] and the Open Targets Platform [41] provide lists of potential drug targets predicted using various databases.”
- The International Mouse Phenotyping Consortium: comprehensive knockout phenotyping underpinning the study of human disease (2022, background): “The IMPC phenotype descriptions listed in the context of genes in the Ensembl genome browser, MGI or the OpenTargets platform are examples of a successful outgoing data integration.”
- Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets (2023, positive): “We performed a phenome-scan of the trans -pQTLs for KITLG using the Open Targets Genetics webtool 59 .”
- The next-generation Open Targets Platform: reimagined, redesigned, rebuilt (2022, methodology): “The Open Targets Platform (https://platform. opentargets.org/) provides an open source informatic solution for the identification and prioritisation of targets using publicly available data (4).”